2016Chin J Kidney Dis Invest(Electronic Edition)Requires access

Progress of precise diagnosis and treatment for Alport syndrome

Jie Ding

Open publisher page 0 citations

Abstract

Alport syndrome is caused by mutations in the COL4A3, COL4A4, and COL4A5 genes encoding the α3, α4, and α5 chains of collagen type Ⅳ, respectively, and is clinically characterized by hematuria, proteinuria, and progressive renal failure, with deafness and ocular lesions in some patients. With new improvement in medical technology, the diagnosis of Alport syndrome has been more and more exact, which was based from initial clinical manifestation to typical ultrastructural pathological changes of GBM, and to currently-widely-used mutations detection. At present, Alport syndrome is considered to be a treatable disease, and early use of angiotensin-converting enzyme (ACE) inhibition and angiotensin receptor blockade (ARB) may delay the onset of renal failure in Alport syndrome patients. Key words: Alport syndrome; Rrenal failure; Diagnosis; Treatment

About this research paper

What this paper is about

Alport syndrome is caused by mutations in the COL4A3, COL4A4, and COL4A5 genes encoding the α3, α4, and α5 chains of collagen type Ⅳ, respectively, and is clinically characterized by hematuria, proteinuria, and progressive renal failure, with deafness and ocular lesions in some patients. With new improvement in medical technology, the diagnosis of Alport syndrome has been more and more exact, which was based from initial clinical manifestation to typical ultrastructural pathological changes of GBM, and to currently-widely-used mutations detection. At present, Alport syndrome is considered to be a treatable disease, and early use of angiotensin-converting enzyme (ACE) inhibition and angiotensin receptor blockade (ARB) may delay the onset of renal failure in Alport syndrome patients. Key words: Alport syndrome; Rrenal failure; Diagnosis; Treatment

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Alport syndrome is caused by mutations in the COL4A3, COL4A4, and COL4A5 genes encoding the α3, α4, and α5 chains of collagen type Ⅳ, respectively, and is clinically characterized by hematuria, proteinuria, and progressive renal failure, with deafness and ocular lesions in some patients. With new improvement in medical technology, the diagnosis of Alport syndrome has been more and more exact, which was based from initial clinical manifestation to typical ultrastructural pathological changes of GBM, and to currently-widely-used mutations detection. At present, Alport syndrome is considered to be a treatable disease, and early use of angiotensin-converting enzyme (ACE) inhibition and angiotensin receptor blockade (ARB) may delay the onset of renal failure in Alport syndrome patients. Key words: Alport syndrome; Rrenal failure; Diagnosis; Treatment

Key concepts: Alport syndrome, Medicine, Proteinuria, Glomerulonephritis, Disease, Pathological, Pathology, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Progress of precise diagnosis and treatment for Alport syndrome — Research Paper | ScholarLens